Downloading...
Download

SYK

GEHC topped out in an ascending channel SHORTGEHC is a new spinoff from General Electric. It has great success thus far with good earnings reports and no dependency on debt and interest rates. It has been on an uptrend since the November earnings. At present it is correcting. I will play this going short on shares while hedging with a long term call options. I am in GE calls out into 2026. A long term call option will yield a lower capital gains tax if closed beyond 12 months. Accordingly, I will go out 15-16 months as I typically want to close early to avoid the effects of time decay. I have high expectations for GEHC. I do not think it will disappoint. When price reaches the running mean anchored VWAP I will close the shares and run only the options.
NASDAQ:GEHCLong
by AwesomeAvani
IRTC Med Tech Device Manufacturer at Fair Value LONGIRTC on the weekly chart shows a symmetrical triangle with compression of price into the apex confluent with the 5 year anchored mean VWAP. I am very familiar with the product line including often lifesaving technology such as AEDs. The company has had weak earnings reports but price has managed to so from undervalued to fair value. I will add to my position here with 20% more. Targets of 140 and 205 are tool drawn onto the chart from pivots of the past. Medical technology is reportedly a hot sector for 2024.
NASDAQ:IRTCLong
by AwesomeAvani
ZBH a medical device company falls on earnings beat LONGZBH is a big global medical device company. It is old school. Aluminum titanium polymers, plates screws wires. Hollywood stars are familiar as it makes the devices for leg lengthening surgery. ( shortening is easy, lengthening not so much) I am familiar because in the past I have served as a consultant for this company. It business is mainly orthopedic elective surgery in supporting orthopedic surgeons serving their patients spine straightening to braces for after a neck fracture. Not a surprise but a lot of surgeries were put off during Covid. So much that the catching up is still ongoing. This is part of the reason why healthcare and the medical technology sectors are expected to be among the hottest of 2024. So much for fundamentals, the technical analysis support for a long trade is commented on the chart. On it you can see the trend since the last earnings. ZBH reported Thursday, January 7th. with an earnings beat and a dip in preparation for a possible rip. The lunch hour of Thursday's session would be the next best time while another time is when you find another dip after you have read this. Want to trade and hedge your trade? Just take a trade in SYK and let them have a race. Cut the underperformer and use the proceeds to get more of the other. It's a very simple plan. Want a broad trade in medical technology? Take a look at XBI or leveraged LABU.
NYSE:ZBHLong
by AwesomeAvani
SYK testing key resistanceStryker Corp. (SYK) presently trading above key resistance, able to absorb weekly selling pressures. A weekly settlement above this resistance zone would place (SYK) into a buy signal where gains of 20% would be expected over the following 3 - 5 months. Inversely, failing to close above this resistance level on a weekly basis, or closing back below this resistance level on a weekly basis, would lead to bearish momentum where losses of 20% would be expected over the same time horizon.
NYSE:SYK
by SpecialeAnalysis
MERCK IS DIRT CHEAP. $11 BILLION CANCER DRUG. SALES BOOMING!We keep seeing Clinical Stage Companies that are publicly traded, with new FDA Approvals, and the stocks are blasting off. Many of those are trading over $100 with no revenue, profits or earnings. Here Merck is, sitting under $100, beating earnings, with record revenue and profit, and paying an almost 3.00% dividend....It is simply outrageous. Wall Street Corruption at it's best! We took a long position at $82.00 several weeks ago. We feel the stock is worth at minimum, $150.00 all day long. KEYTRUDA alone, not counting any other products manufactured / developed by Merck, or any other divisions of Merck, is forecast to bring in over $11 Billion in sales. Holding for the almost 3% Dividend and for the stock price appreciation into the future. 250,000 LONG @ $82.00 Best of Luck Everyone!
NYSE:MRKLong
by UnknownUnicorn3159981